Oral preparations for fluid and electrolyte imbalance
09.02.01.01
Oral potassium
Potassium Chloride (Sando-K®)
Formulary
Sando K®
Effervescent Tablets
Potassium Chloride
Formulary
Kay Cee L®
Syrup
09.02.01.01
Potassium removal
Polystyrene Sulphonate Resins (Calcium Resonium®)
Formulary
09.02.01.02
Oral sodium and water
09.02.01.02
Oral rehydration therapy (ORT)
Oral Rehydration Salts (Dioralyte®)
Formulary
Drug included within CCG low priority prescribing policy. EXEMPTIONS EXIST FOR CERTAIN INDICATIONS. Please consult attached policy for list of excepted indications for prescribing of this drug.
09.02.01.03
Oral bicarbonate
Sodium Bicarbonate (oral)
Formulary
09.02.02
Parenteral preparations for fluid and electrolyte imbalance
For Children with Cystic Fibrosis with pancreatic Insufficiency
Capsules
Solution - if unable to swallow capsules
09.06.01
Vitamin A
Vitamins A and D (Halibut-liver oil)
Formulary
Drug included within CCG low priority prescribing policy. EXEMPTIONS EXIST FOR CERTAIN INDICATIONS. Please consult attached policy for list of excepted indications for prescribing of this drug.
Drug included within CCG low priority prescribing policy. EXEMPTIONS EXIST FOR CERTAIN INDICATIONS. Please consult attached policy for list of excepted indications for prescribing of this drug.
09.06.04
Vitamin D
Alfacalcidol
Formulary
One -Alpha®
Colecalciferol
Formulary
Plenachol® 20,000 unit and 40,000 unit capsules
Colecalciferol
Formulary
400 unit capsule & 800 unit capsule
Drug included within CCG low priority prescribing policy. EXEMPTIONS EXIST FOR CERTAIN INDICATIONS. Please consult attached policy for list of excepted indications for prescribing of this drug.
Colecalciferol and Calcium Carbonate
Formulary
Adcal D3; Calcichew D3 forte; Accrete D3
Ergocalciferol (Injection)
Formulary
09.06.05
Vitamin E
Alpha Tocopheryl Acetate (Vitamin E)
Formulary
09.06.06
Vitamin K
Menadiol Sodium Phosphate
Formulary
Phytomenadione (Konakion® MM)
Formulary
Konakion® MM Paediatric; oral, IM or IV injection
Konakion® MM; Slow IV injection or IV infusion
09.06.07
Multivitamin preparations
Multivitamin preparations (Dalivit®)
Formulary
Drug included within CCG low priority prescribing policy. EXEMPTIONS EXIST FOR CERTAIN INDICATIONS. Please consult attached policy for list of excepted indications for prescribing of this drug.
Mutivitamin
Formulary
Drug included within CCG low priority prescribing policy. EXEMPTIONS EXIST FOR CERTAIN INDICATIONS. Please consult attached policy for list of excepted indications for prescribing of this drug.
09.06.07
Vitamin and mineral supplements and adjuncts to synthetic diets
Vitamin and mineral supplements (Forceval®)
Formulary
Drug included within CCG low priority prescribing policy. EXEMPTIONS EXIST FOR CERTAIN INDICATIONS. Please consult attached policy for list of excepted indications for prescribing of this drug.
09.07
Bitters and tonics
09.08
Metabolic disorders
09.08.01
Drugs used in metabolic disorders
Ubidecarenone
Formulary
09.08.01
Wilsons disease
Penicillamine
Formulary
09.08.01
Carnitine deficiency
Levocarnitine (Carnitor®)
Formulary
09.08.01
Fabry's disease
09.08.01
Gaucher's disease
09.08.01
Mucopolysaccharidosis I
09.08.01
Pompe disease
09.08.01
Nephropathic cystinosis
Mercaptamine (Cystagon®)
Formulary
09.08.01
Urea cycle disorders
Sodium Benzoate
Formulary
Sodium Phenylbutyrate (Ammonaps®)
Formulary
09.08.02
Acute porphyrias
09.08.02
Drugs unsafe for use in acute porphyrias
....
Key
Notes
Section Title (top level)
Section Title (sub level)
First Choice item
Non Formulary section
Restricted Drug
Unlicensed
Display tracking information
Link to adult BNF
Link to children's BNF
Link to SPCs
Scottish Medicines Consortium
Cytotoxic Drug
Controlled Drug
High Cost Medicine
Cancer Drugs Fund
NHS England
Homecare
CCG
Traffic Light Status Information
Status
Description
Suitable for prescribing in primary care following recommendation or initiation by a specialist.
Little or no specific monitoring required.
Patient may need a regular review, but this would not exceed that required for other medicines routinely prescribed in primary care.
Brief prescribing document or information sheet may be required.
Suitable for prescribing in primary care following recommendation or initiation by a specialist.
Minimal monitoring required.
Patient may need a regular review, but this would not exceed that required for other medicines routinely prescribed in primary care.
Full prior agreement about patient’s on-going care must be reached under the shared care agreement.
Initiated by specialist and transferred to primary care following a successful initiation period.
Significant monitoring required on an on-going basis.
Full prior agreement about patient’s on-going care must be reached under the shared care agreement.
Suitable for enhanced service.
NOT recommended for use by the NHS in Lancashire.
Includes medicines that NICE has not recommended for use and terminated technology appraisals, unless there is a local need.
Products shown as blue have different Traffic Light List classifications dependent on indication. See the accompanying text next to the product for further information
Appropriate for initiation and ongoing prescribing in both primary and secondary care.
Generally, little or no routine drug monitoring is required.
Low Priority for Prescribing - see Low Priority for Prescribing Policy
Medicine is supplied by the hospital for the duration of the treatment course.
Primary care initiation or continuation of treatment is not recommended unless exceptional circumstances such as specialist GP.
Restricted
Unlicensed
